bictegravir/emtricitabine/tenofovir vs dofetilide
Side-by-side comparison of bictegravir/emtricitabine/tenofovir and dofetilide. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
major Known Drug Interaction
Coadministration of BIKTARVY with drugs that are substrates of OCT2 and MATE1 (e.g., dofetilide) may increase their plasma concentrations (see Table 3 ). Clinical Comment Antiarrhythmics: dofetilide ↑ Dofetilide Coadministration is contraindicated due to the potential for serious and/or life-threatening events associated with dofetilide therapy [see Contraindications (4) ] .
Recommendation: These drugs must not be used together. Your doctor will need to find an alternative treatment to avoid serious heart risks.
Biktarvy
Tikosyn
Biktarvy is a complete HIV-1 treatment for adults and children who weigh at least 31 pounds. It combines three medicines into one tablet to help control the virus.
Dofetilide (Tikosyn) helps keep your heart in a normal rhythm if you have atrial fibrillation or atrial flutter. It can also help convert these abnormal rhythms back to normal.
Biktarvy treats Human Immunodeficiency Virus type 1 (HIV-1) in adults and children weighing at least 31 pounds. It can be used if you have never taken HIV medicine before. It can also replace your current HIV medicine if your virus is under control and you have no resistance to Biktarvy's components.
This medicine is used to maintain a normal heart rhythm if you have atrial fibrillation or atrial flutter for more than a week, and your heart has been returned to a normal rhythm. It can also convert atrial fibrillation and atrial flutter to a normal rhythm. This medicine is for people who have bothersome symptoms from their atrial fibrillation or flutter.
Biktarvy contains three drugs that each block HIV in different ways. Bictegravir stops HIV from inserting its DNA into your cells. Emtricitabine and tenofovir alafenamide interfere with an enzyme HIV needs to make copies of itself.
Dofetilide belongs to a class of drugs called Class III antiarrhythmics. It works by changing the electrical activity in your heart. This helps to stabilize your heart rhythm and prevent irregular heartbeats.
- • Diarrhea
- • Nausea
- • Headache
- • Headache
- • Chest pain
- • Dizziness
No adverse event reports.
- Irregular heartbeat 1,059
- Shortness of breath 603
- Feeling lightheaded 552
- Feeling tired 521
- Death 478
If you have both HIV and hepatitis B, stopping Biktarvy can cause your hepatitis B to suddenly get worse. Your doctor will need to monitor your liver closely for several months after you stop taking Biktarvy. You may need to take medicine for hepatitis B.
This drug can cause life-threatening heart rhythm problems. To lower this risk, you must start or restart this medicine in a hospital where your heart can be watched closely for at least 3 days. The hospital staff will check your kidney function and heart rhythm regularly.
There is a pregnancy registry to track outcomes in women who take Biktarvy during pregnancy. Talk to your doctor about the risks and benefits of taking Biktarvy if you are pregnant or planning to become pregnant. There is not enough data to assess the risk of major birth defects.
Tell your doctor if you are pregnant or plan to become pregnant. It is not known if this medicine will harm your unborn baby. Talk to your doctor about the risks and benefits of taking this medicine while pregnant or breastfeeding.
Also Compare, Nearby Drugs
Compare bictegravir/emtricitabine/tenofovir with
Compare dofetilide with
How to Read This bictegravir/emtricitabine/tenofovir vs dofetilide Comparison
bictegravir/emtricitabine/tenofovir is classified in the Integrase Inhibitor / NRTI Combination drug class, while dofetilide sits within the Class III Antiarrhythmic class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, bictegravir/emtricitabine/tenofovir has 0 submissions while dofetilide has 3,213. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known major interaction flagged in FDA labeling, attributed to the hiv medicine blocks the way your body removes the heart medicine dofetilide, causing it to build up to dangerous levels. high levels of dofetilide can cause life-threatening heart rhythm problems.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between bictegravir/emtricitabine/tenofovir and dofetilide - always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.